Heartflow, known for its AI-based CCTA evaluations, appears to be going public. The news follows years of momentum for the California-based company, including improved Medicare reimbursements for cardiac CT and a new Category I CPT code for its Plaque Analysis software.

One of the study's most significant findings was that patients managed using the advanced AI software saw LDL cholesterol drops of 18.7 mg/dL, with a 15% reduction in their risk of a cardiac event. Even patients with no calcified plaque saw significant changes in care management.

The numbers from Pittsburgh are staggering. And they’re all about blasting American-made AI into the stratosphere, if not to Infinity and beyond. 

Receivers on active glucose monitors manufactured by Dexcom are reportedly failing to send alerts when a patient’s blood sugar levels are dangerously high or low. There have been no deaths linked to the malfunction. 

Philips has launched a new 'AI Marketplace' that expands access to third-party diagnostic tools. The company's goal is to put a variety of offerings into one convenient location for clinicians.

In hospital settings, the success of AI adoption hinges on how well implementation leaders balance technological innovation in departmental silos with operational nimbleness across the enterprise. In a term, the latter refers to hospital logistics. 

In his drive to keep China from sprinting ahead of the U.S. in the AI arms race, President Trump may be willing to cut some risky corners.

Within healthcare, artificial intelligence and quality improvement have some things in common. 

The first FDA-cleared AI model of its kind was found to be an accurate screening tool for cardiac amyloidosis.

In the past year, there has been a record number of new medical AI submissions, resulting in 300 new clinical AI clearances. The number of submissions has been steadily rising over the past decade.